Consistent with our above finding, PDCD2L expression was increased in BLCA, BRCA, Cholangio carcinoma (CHOL), Colon adenocarcinoma(COAD), Esophageal carcinoma (ESCA), Head and Neck squamous cell carcinoma (HNSC), HNSC-HPVpos, KICH, KIRC, KIRP, LIHC, Lung adenocarcinoma (LUAD), LUSC, Prostate adenocarcinoma (PRAD), Rectum adenocarcinoma (READ), STAD, Thyroid carcinoma (THCA) and Uterine Corpus Endometrial Carcinoma (UCEC) (Fig. 1B).To explore the relationship between PDCD2L expression and clinical stage of pan-cancer, we performed further analysis by GEPIA2. The gene discussed is PDCD2L; the disease is cancer.